Table 3 Summary of findings for length of hospital stay outcomes [35]
Burden of disease measure | Type of antimicrobial resistance | Number of participants (studiesa) | Absolute effect, sMD (95% CI) | Certainty of the evidence (GRADE)b | Commentc |
|---|---|---|---|---|---|
Total LOS | Third-generation cephalosporin | 888 (5 studies) | sMD not calculated due to considerable heterogeneity |
| Downgraded due to serious inconsistency and imprecision |
Quinolone | 646 (8 studies) | sMD not calculated due to substantial to considerable heterogeneity |
| Downgraded due to serious inconsistency and imprecision | |
MDR | – | – | – | Only reported in 1 study, meta-analysis and GRADE assessment not performed | |
Post-infection LOS | Third-generation cephalosporin | 538 (2 studies) | 7.16Â days higher (2.76 higher to 11.57 higher) |
| Downgraded due to serious imprecision. Evidence to support upgrading outweighed by evidence to support downgrading. |
Quinolone | – | – | – | Not reported | |
MDR | – | – | – | Not reported |
